- Home
- LEE vs CRBP Comparison
LEE vs CRBP Comparison
Compare LEE & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEE
- CRBP
- Stock Information
- Founded
- LEE 1890
- CRBP 2009
- Country
- LEE United States
- CRBP United States
- Employees
- LEE N/A
- CRBP N/A
- Industry
- LEE Newspapers/Magazines
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- LEE Consumer Discretionary
- CRBP Health Care
- Exchange
- LEE Nasdaq
- CRBP Nasdaq
- Market Cap
- LEE 52.7M
- CRBP 73.4M
- IPO Year
- LEE N/A
- CRBP N/A
- Fundamental
- Price
- LEE $7.80
- CRBP $6.65
- Analyst Decision
- LEE
- CRBP Strong Buy
- Analyst Count
- LEE 0
- CRBP 10
- Target Price
- LEE N/A
- CRBP $53.56
- AVG Volume (30 Days)
- LEE 15.4K
- CRBP 148.0K
- Earning Date
- LEE 05-08-2025
- CRBP 05-06-2025
- Dividend Yield
- LEE N/A
- CRBP N/A
- EPS Growth
- LEE N/A
- CRBP N/A
- EPS
- LEE N/A
- CRBP N/A
- Revenue
- LEE $591,094,000.00
- CRBP N/A
- Revenue This Year
- LEE N/A
- CRBP N/A
- Revenue Next Year
- LEE N/A
- CRBP $150.00
- P/E Ratio
- LEE N/A
- CRBP N/A
- Revenue Growth
- LEE N/A
- CRBP N/A
- 52 Week Low
- LEE $7.57
- CRBP $4.64
- 52 Week High
- LEE $19.63
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- LEE 36.57
- CRBP 48.86
- Support Level
- LEE $7.97
- CRBP $6.10
- Resistance Level
- LEE $8.80
- CRBP $8.07
- Average True Range (ATR)
- LEE 0.44
- CRBP 0.70
- MACD
- LEE -0.01
- CRBP -0.07
- Stochastic Oscillator
- LEE 24.86
- CRBP 26.50
About LEE Lee Enterprises Incorporated
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.